Format

Send to

Choose Destination
Haematologica. 2017 Apr;102(4):e156-e159. doi: 10.3324/haematol.2016.151738. Epub 2016 Dec 15.

Efficacy and safety of idelalisib in patients with relapsed, rituximab- and alkylating agent-refractory follicular lymphoma: a subgroup analysis of a phase 2 study.

Author information

1
Hospices Civils de Lyon, University Claude Bernard, Pierre Benite, France.
2
Lymphoma Program, Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA, USA.
3
Department of Hematology/Oncology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
4
Departments of Oncology and Hematologic Malignancies, Johns Hopkins University, Baltimore, MD, USA.
5
Department of Internal Medicine III, University Hospital of Ulm, Germany.
6
Division of Hematology, Ohio State University Wexner Medical Center, Columbus, OH, USA.
7
Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA, USA.
8
Department of Hematology, Jagiellonian University, Krakow, Poland.
9
Hematologic Malignancies Research Program, Sarah Cannon Research Institute, Nashville, TN, USA.
10
Department of Medicine, Oncology Division, Washington University School of Medicine, St Louis, MO, USA.
11
Division of Hematology/Oncology, Weill Cornell Medical College, NY, USA.
12
Gilead Sciences Inc., Foster City, CA, USA.
13
At the time of the analyses, Gilead Sciences Inc., Foster City, CA, USA.
14
Institute of Hematology and Oncology, University of Bologna, Italy.
15
Medical Oncology Division, University of Washington School of Medicine, Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA agopal@u.washington.edu.
PMID:
27979923
PMCID:
PMC5395130
DOI:
10.3324/haematol.2016.151738
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center